Epidermal Growth Factor Recetor mutation study for 5 years,in a population of patients with non-small cell lung cancer [Estudo da mutação do recetor do fator de crescimento epidérmico,durante 5 anos,numa população de doentes com cancro do pulmão de não pequenas células]

Introduction: in 2006,the vila nova de gaia/espinho hospital centre pulmonary oncology unit started performing egfr (epidermal growth factor receptor) mutation sequencing in selected patients with nsclc and systematically in all patients since 2010,regardless of histology,smoking habits,age or sex. the aim of this study was to characterize the group of patients that carried out the sequencing between 2006-2010,to determine egfr mutation frequency,to evaluate the overall survival and the survival after the use of tyrosine kinase inhibitors (tki),in patients who performed this therapy in second and third line,knowing the egfr mutation status. methods: descriptive statistical analysis of patients who did egfr sequencing in 2006-2010 and of overall survival in patients treated with tki as 2nd and 3rd line therapy. record of the material available for analysis and average delay of exam results,according to the material submitted. results: the sequencing was performed in 374 patients,71,1% males,67,1% non/ex-smokers,32,9% smokers,57,8% adenocarcinoma and 23,5% squamous cell carcinoma (scc). the mutation was detected in 49 patients (13,1%). in all studied patients,the mutation rate was 9% in males and 23% in females. median overall survival after erlotinib use of was 14 months for patients with positive egfr mutation versus 6 months in not mutated patients (p = 0.003). conclusion: our group had an overall mutation rate of 13.1% with female,non-smokers,adenocarcinoma histology predominance. in selected patients (2006/2009),the mutation rate was 16%,in not selected patients (2010) the mutation rate was 10.4%. this study has permitted a better understanding of the egfr mutation rate in the portuguese population as welll as an evaluation of the patients survival after the use of of tyrosine kinase inhibitors,in second and third line therapy with previous knowledge of the egfr mutational status. statistical significant differences in survival were found in the two patient groups (egfr mutated and non mutated). the egfr mutation research should be performed in all patients with nsclc,giving the possibility to a considerable number of patients to perform a first line treatment with tki (egfr mutated patients) and the advantage of performing other chemotherapy schemes,when progression occurs. © 2012 sociedade portuguesa de pneumologia.